Takeda presenta en ESID 2026 los resultados del estudio IgGNITE de fase 2/3 de TAK-881, una terapia subcutánea en investigación para la inmunodeficiencia primaria (IDP)

OSAKA, Japón, y CAMBRIDGE, Massachusetts–(BUSINESS WIRE)–.

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.